昆藥集團(600422.SH):2021年度第一期超短期融資券完成兑付
格隆匯7月20日丨昆藥集團(600422.SH)公吿,公司於2021年4月21日在全國銀行間債券市場成功發行了昆藥集團股份有限公司2021年度第一期超短期融資券,債券簡稱:21昆藥集SCP001,債券代碼:012101566,發行總額1億元人民幣,期限90天,票面利率為4.40%,到期兑付日期為2021年7月20日。
2021年7月20日,公司已完成了本期融資券的兑付工作,本息兑付總額共計人民幣101,084,931.51元,由銀行間市場清算所股份有限公司代理劃付至債券持有人指定的銀行賬户。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.